aTyr Pharma, Inc.
ATYRHealthcare|Biotechnology|US
$6.35
+0.32 (+5.31%)
Tangible Book / Share
$13.76
Cash / Share
$20.46
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05892614 Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) | Interstitial Lung Disease | P2 | Recruiting | 25 | RCT, Double-blind | efzofitimod 450 mg, efzofitimod 270 mg, Placebo |
| NCT05415137 Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | P3 | Completed | 268 | RCT, Double-blind | Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo |
| NCT04412668 Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 | SARS-CoV-2 (COVID-19) Severe Pneumonia | P2 | Completed | 36 | RCT, Double-blind | Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo |
| NCT02579239 Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) | Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy | P1P2 | Completed | 18 | Open-label | ATYR1940, Placebo |
| NCT02836418 Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) | Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy | P1P2 | Completed | 8 | Open-label | ATYR1940 |
| NCT02531217 Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension | Facioscapulohumeral Muscular Dystrophy | P1P2 | Completed | 9 | Open-label | ATYR1940 |
| NCT02603562 Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy (FSHD) | P1P2 | Completed | 8 | Open-label | ATYR1940 |
| NCT02239224 Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy (FSHD) | P1P2 | Completed | 20 | RCT, Double-blind | Placebo, ATYR1940 |
| NCT03824392 Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | P1P2 | Completed | 37 | RCT, Double-blind | Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo |
| NCT01437345 A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD | Facioscapulohumeral Muscular Dystrophy | Completed | 53 | — | — |